This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
What Are the National and Global Recommendations for Pneumococcal Vaccination in Oncology Patients?
The NCCN (2020) Clinical Practice Guidelines and ESMO (2013) recommend pneumococcal vaccination in splenectomy, HSCT and other cancer patients on immunosuppressive therapy.1,2 The NCCN 2020 guidelines mention that both pneumococcal vaccines, PCV13 and PPSV23, are well tolerated for adult cancer survivors, and should be considered and encouraged for these survivors (PCV13 for adult survivors aged ≥50 years).3 The CDC’s ACIP (2019) recommends the use of PCV13 and PPSV23 in adults with splenectomy, leukaemia, lymphoma, Hodgkin’s disease, generalised malignancy and multiple myeloma (PCV13 for adults aged ≥50 years). The ACIP recommends 1 dose of PCV13 in persons aged ≥50 years; in persons aged between 50 and 64 years, 1 dose of PPSV23 is recommended ≥8 weeks after PCV13 and ≥5 years after any PPSV23 at the age of <65 years. In persons aged ≥65 years, 1 dose of PCV13 is recommended, if not received PCV13 previously. For PPSV23 in this age group, 1 dose is recommended ≥8 weeks after PCV13 and ≥5 years after any PPSV23 at the age of <65 years.3 The guidelines of the AGIHO of the DGHO recommend the use of PCV13 followed by PPSV23 within 6 to 12 weeks in patients with cancer in adulthood (PCV13 for adult survivors aged ≥50 years).4 The ASBMT (2011) and HCRC/SCCA (2014) guidelines recommend the use of PCV in patients with HSCT/HCT.5,6
Various national guidelines, including the IMA (2018)7 and the IAOH (2020) recommend pneumococcal vaccination in oncohaematological patients. The IMA recommends the administration of PCV13 in adult patients with cancer aged ≥50 years at least 3 months after chemotherapy; PPSV23 is recommended at least after 8 weeks of PCV13 administration. The IAOH recommends the use of PCV13 in series with PPSV23 in adult patients with cancer aged ≥50 years.8
ACIP, Advisory Committee on Immunization Practices; AGIHO, The German Society for Hematology and Medical Oncology; ASBMT, American Society for Blood and Marrow Transplantation; CDC, Centers for Disease Control and Prevention; CLL, chronic lymphatic leukaemia; ESMO, European Society for Medical Oncology; HCRC, Harvard Cancer Research Center; HCT, haematopoietic cell transplant; HSCT, haematopoietic stem cell transplant; IAOH, Indian Association of Occupational Health; NCCN, National Comprehensive Cancer Network; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine; SCCA, Seattle Cancer Care Alliance.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0661 July 2023
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.